Clinical trial NCT04414930: Pharmacologic Augmentation of Targeted Cognitive Training in Schizophrenia
Official title: Pharmacologic Augmentation of Targeted Cognitive Training in Schizophrenia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Schizophrenia
Schizoaffective Disorder
Lead sponsor: University of California, San Diego
Sponsor class: OTHER
First posted: 2020-06-04
Enrollment: 28
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: These studies look to conduct efficient pilot testing of a novel intervention strategy for chronic psychotic disorders - Pharmacologic Augmentation of Cognitive Therapy (PACT) - via an experimental medicine approach. Antipsychotics are the major therapeutic tool for chronic psychotic disorders, including schizophrenia, but do not significantly alter their course or real-life impact. Specific cognitive therapies achieve modest symptom reduction and improved function and cognition in psychosis patients, including "bottom-up" sensory-based targeted cognitive training (TCT). While benefits of TCT are evident at the group level, almost half of all patients demonstrate little or no cognitive gains after 30-40 hours (h) of TCT. For patients and clinicians, the costs and logistical complexities associated with these time- and resource-intensive interventions can be prohibitive. We propose and will test a novel "augmentation strategy" for using medications to specifically enhance the benefits of TCT in schizophrenia.

Detailed description: Subjects who meet criteria for study entry come to UCSD where consenting and a comprehensive screening and diagnostic assessment including a Mini-International Neuropsychiatric Interview are conducted. After initial screening, subjects return twice, approximately 7 days apart, for biomarker assessment after challenge with placebo (PBO) (Test 1) or amphetamine 5 mg po (AMPH) (Test 2). Subjects then enter the "treatment phase", completing up to 30 one-hour targeted cognitive training (TCT) sessions. Subjects are randomized to one of 2 groups: "AMPH Group" receive AMPH (5 mg po) 1h before each TCT session; "PBO Group" receive PBO dosed identically to AMPH. Pill identity (AMPH vs. PBO) is blind to subjects and staff.

TCT sessions are scheduled approximately 3 times each week for 10 weeks. TCT consists of 7 computerized exercises delivered on standardized laptops and headphones. Collectively, these exercises target learning mechanisms involving auditory perception and processing speed (Sound Sweeps, Fine Tuning) and auditory memory (Syllable Stacks, Memory Grid, To-Do List Training, Rhythm Recall, Hear-Hear). Training is structured into blocks that deliver stimulus sets with varying temporal and psychophysical parameters to allow continuous learning and improvement. Blocks consist of 10-35 adaptive trials where the subject's progression depends on their performance. Exercises apply an n-up/m-down algorithm to responses to estimate psychophysical thresholds while ensuring that participants remain engaged and challenged at an appropriate level (\~80% accuracy) as their abilities improve.

Clinical and functional outcome measures are acquired at "baseline", and 1-2 days after completion of 10, 20 and 30 TCT sessions and 12 weeks post-training. Urine toxicology screens and Columbia Suicide Severity Rating Scales are performed at least weekly, prior to a TCT session. A treatment satisfaction scale (100 mm line) rates expectations at the start of the study and actual experience of treatment in three areas: "satisfaction", "hard work" and "worthwhile." Subjects from both groups return to UCSD 12 weeks after the TCT has ended, and outcome measures are reassessed to test the "durability" of benefits.

Eligibility criteria: Inclusion criteria include:

* DSM-IV diagnosis of schizophrenia or schizoaffective disorder, depressed type
* Written informed consent to participate in the study
* Age 18 - 55
* Absence of dementia or mental retardation
* Urine toxicology negative for recreational drugs
* Fluent and literate in English (needed for completion of WIN and QuickSIN)

Exclusion criteria include:

* Meets DSM-IV criteria for current substance abuse or dependence and has been substance abstinent for less than 30 days
* A history of traumatic brain injury
* Auditory or visual impairments severe enough to prevent study participation
* Under conservatorship (determined by Anasazi)
* Pregnancy

Primary outcomes:
measure: Primary Clinical Outcome
timeFrame: approximately 22 weeks
measure: Primary Functional Outcome
timeFrame: approximately 22 weeks
measure: Primary Neurocognitive Outcome
timeFrame: approximately 22 weeks
Secondary outcomes:
measure: Secondary Clinical Outcome Measures
timeFrame: approximately 22 weeks
measure: Secondary Neurocognitive Outcome Measures
timeFrame: approximately 22 weeks
measure: Psychotic Symptoms
timeFrame: approximately 22 weeks
measure: Manic Symptoms
timeFrame: approximately 22 weeks
measure: Current Depressive Symptoms
timeFrame: approximately 22 weeks
measure: Abnormal Involuntary Movements
timeFrame: approximately 22 weeks
measure: Suicidal Ideation
timeFrame: approximately 22 weeks
measure: Amphetamine Withdrawal Symptoms
timeFrame: approximately 22 weeks
measure: Treatment satisfaction
timeFrame: approximately 22 weeks
Other outcomes:
Locations:
city: San Diego
country: United States
facility: Clinical Teaching Facility (CTF-B102) at UCSD Medical Center
state: California
Study officials:
affiliation: UC San Diego
name: Neal R Serdlow, M.D., Ph.D.
role: PRINCIPAL_INVESTIGATOR
References: